Literature DB >> 6613833

Effect of amiodarone in paroxysmal supraventricular tachycardia with or without Wolff-Parkinson-White syndrome.

H J Wellens, P Brugada, H Abdollah.   

Abstract

In Wolff-Parkinson-White (WPW) syndrome, the two most commonly occurring arrhythmias are circus movement tachycardia (CMT) and atrial fibrillation (AF). In 70% of patients with clinically documented CMT in whom the arrhythmia could be initiated by programmed electrical stimulation of the heart, the same CMT could still be initiated after long-term oral amiodarone administration. Spontaneous clinical recurrence of the arrhythmia was, however, observed in only 10% of patients. This finding suggests that the beneficial effect of amiodarone on CMT is primarily based on the prevention of the CMT-initiating premature beat. This may also apply to atrioventricular nodal reentrant tachycardia, in which amiodarone is also extremely effective in preventing relapses. The role of amiodarone in other forms of reentrant, or ectopic, supraventricular tachycardias is less well defined. During AF in WPW syndrome, the ventricular rate is related to the duration of the anterograde refractory period of the accessory pathway. Amiodarone prolongs this value, resulting in the reduction of ventricular rate during AF. Unfortunately, in the presence of a short anterograde refractory period of the accessory pathway, amiodarone results in only a small amount of lengthening of this value. In these patients the beneficial effect of amiodarone may primarily be related to the prevention of episodes of AF. We also found that the effect of oral amiodarone on the duration of the anterograde refractory period of the accessory pathway can (1) be abolished by sympathetic stimulation with isoproterenol and (2) be predicted from the effect of ajmaline or procainamide given intravenously. These observations clearly have practical clinical implications.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6613833     DOI: 10.1016/0002-8703(83)90010-8

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  7 in total

Review 1.  Risk-benefit assessment of amiodarone in the treatment of cardiac arrhythmias.

Authors:  P J Counihan; W J McKenna
Journal:  Drug Saf       Date:  1990 Jul-Aug       Impact factor: 5.606

2.  Comparison of the Length of Hospital Stay between the Patients with Atrial Fibrillation Treated with Amiodarone and Patients with Normal Sinus Rhythm after Coronary Artery Bypass Graft.

Authors:  Samad Shams Vahdati; Jahanbakhsh Samadikhah; Seied Hadi Hakim; Rasoul Azarfarin; Mahsa Ansarin
Journal:  J Cardiovasc Thorac Res       Date:  2012-02-17

Review 3.  Amiodarone in long term prophylaxis.

Authors:  D Katritsis; A J Camm
Journal:  Drugs       Date:  1991       Impact factor: 9.546

4.  Effects of intravenous dofetilide on induction of atrioventricular re-entrant tachycardia.

Authors:  S M Cobbe; R W Campbell; A J Camm; A W Nathan; E Rowland; P E Bloch-Thomsen; M Møller; L Jordaens
Journal:  Heart       Date:  2001-11       Impact factor: 5.994

Review 5.  Is there a future for antiarrhythmic drug therapy?

Authors:  P G Guerra; M Talajic; D Roy; M Dubuc; B Thibault; S Nattel
Journal:  Drugs       Date:  1998-11       Impact factor: 9.546

Review 6.  Amiodarone. An overview of its pharmacological properties, and review of its therapeutic use in cardiac arrhythmias.

Authors:  J Gill; R C Heel; A Fitton
Journal:  Drugs       Date:  1992-01       Impact factor: 9.546

7.  Amiodarone treatment in patients with ventricular arrhythmias.

Authors:  E N Prystowsky; J J Heger; W M Miles; D P Zipes
Journal:  Drugs       Date:  1985-03       Impact factor: 9.546

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.